1. Synthesis of NVS-BPTF-1 and evaluation of its biological activity. (1st September 2021) Authors: Mélin, Léa; Calosing, Cyrus; Kharenko, Olesya A.; Hansen, Henrik C.; Gagnon, Alexandre Journal: Bioorganic & medicinal chemistry letters Issue: Volume 47(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells. (June 2018) Authors: Tsujikawa, Laura; Kulikowski, Ewelina; Calosing, Cyrus; Wasiak, Sylwia; Gilham, Dean; Halliday, Christopher; Johansson, Jan; Sweeney, Mike; Wong, Norm Journal: Atherosclerosis Issue: Volume 32(2018) Page Start: 104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BET inhibitor apabetalone (RVX-208) downregulates the complement cascade in primary human hepatocytes, in mice and in cardiovascular disease human patients. (September 2017) Authors: Wasiak, Sylwia; Gilham, Dean; Tsujikawa, Laura M.; Halliday, Christopher; Calosing, Cyrus; Jahagirdar, Ravi; Johansson, Jan; Sweeney, Michael; Wong, Norman C.; Kulikowski, Ewelina Journal: Molecular immunology Issue: Volume 89(2017:Sep.) Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity. (August 2017) Authors: Kulikowski, Ewelina; Calosing, Cyrus; Tsujikawa, Laura; Wasiak, Sylwia; Gilham, Dean; Halliday, Christopher; Johansson, Jan; Sweeney, Michael; Wong, Norman Journal: Atherosclerosis Issue: Volume 263(2017) Page Start: e113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗